SOP CRS und HIPEC für peritoneale Metastasen mit gastrointestinalem Ursprung

Die peritoneal metastasierten Malignome des Gastrointestinaltrakts stellen eine therapeutische Herausforderung dar. Die makroskopisch komplette zytoreduktive Chirurgie (CRS) gefolgt von hyperthermer intraperitonealer Chemotherapie (HIPEC) ermöglicht eine substanzielle Verbesserung des Outcomes bei hochselektionierten Patienten gegenüber alleiniger systemischer Chemotherapie [1]. Diese SOP beschreibt die Auswahlkriterien und das Vorgehen.

Schlüsselwörter

komplette zytoreduktive Chirurgie - hypertherme intraperitoneale Chemotherapie - peritoneal metastasierte gastrointestinale Tumoren - Pseudomyxoma peritonei - Peritonealkarzinose

Publication History

Article published online:
13 December 2021

• Literatur

• 1 Huang C, Min Y, Wang S. et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget 2017; 8: 55657-55683
• 2 AWMF. S3-Leitlinie Kolorektales Karzinom. 2019. Im Internet (Stand: 01.10.2020): http://www.awmf.org/uploads/tx_szleitlinien/021-007OLl_S3_Kolorektales-Karzinom-KRK_2019-01.pdf
• 3 AWMF. S3-Leitlinie Magenkarzinom. 2019. Im Internet (Stand: 01.10.2020): http://www.awmf.org/uploads/tx_szleitlinien/032-009OLl-KF_Magenkarzinom_2019-01.pdf
• 4 Esquivel J, Sticca R, Sugarbaker P. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement. Ann Surg Oncol 2007; 14: 128-133
• 5 Cavaliere F, De Simone M, Virzì S. et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol 2011; 37: 148-154
• 6 Blaj S, Nedelcut S, Mayr M. et al. Re-operations for early postoperative complications after CRS and HIPEC: indication, timing, procedure and outcome. Langenbecks Arch Surg 2019; 404: 541-546
• 7 Quenet F, Elias D, Roca L. et al. UNICANCER-GI Group and the French BIG-Renape Group. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 2018; 36 (18 Suppl.): LBA3503
• 8 Bakkers C, van Erning FN, Rovers KP. et al. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study. Eur J Surg Oncol 2020; 46: 1902-1907
• 9 Moran B, Cecil T, Chandrakumaran K. et al. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis 2015; 17: 772-778
• 10 Benhaim L, Faron M, Gelli M. et al. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei. Surg Oncol 2019; 29: 78-83
• 11 Glockzin G, Zeman F, Kroner RS. et al. Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastases: Results of the prospective multicenter phase 2 COMBATAC trial. Clin Colorectal Cancer 2018; 17: 285-296
• 12 Piso P, Stierstorfer K, Gerken M. et al. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer. Int J Colorectal Dis 2018; 33: 1559-1567
• 13 Bonnot PE, Piessen G, Kepenekian V. et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): A propensity score analysis. J Clin Oncol 2019; 37: 2028-2040
• 14 Rau B, Brandl A, Piso P. et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer 2020; 23: 11-22